Ignite Creation Date:
2025-12-25 @ 1:38 AM
Ignite Modification Date:
2026-03-02 @ 4:06 AM
Study NCT ID:
NCT00250094
Status:
COMPLETED
Last Update Posted:
2011-09-07
First Post:
2005-11-03
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Clinical Benefit of Topoisomerase Downregulation
Sponsor:
New Mexico Cancer Research Alliance
Organization:
Study Overview
Official Title:
Clinical Benefit of Topoisomerase Downregulation: A Phase I Pilot Study
Status:
COMPLETED
Status Verified Date:
2011-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
1.1 To determine the regulation of topoisomerase I and II following alternating prolonged exposure to topotecan and etoposide (VP-16)
1.2 To determine the time to progression and the objective response rate of this treatment in patients with incurable ovarian cancer.
1.2 To determine the time to progression and the objective response rate of this treatment in patients with incurable ovarian cancer.
Detailed Description:
The rationale to study the downregulation of topoisomerase enzyme in ovarian cancer in relationship to the cell cycle distribution of the cancer cells after a prolonged continuous exposure to topo I and II poisons is to better understand the relationship between cell cycle and topo poisoning, which may lead to better clinical trial designs.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: